Journal articles: 'Soluble interleukin-2 receptor'

1

Murakami, Saburo. "Soluble interleukin-2 receptor in cancer." Frontiers in Bioscience 9, no. 1-3 (2004): 3085. http://dx.doi.org/10.2741/1461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Huang, Andy, and Kirsten S. Hindle. "Serum soluble interleukin-2-receptor concentrations." Lancet 358, no. 9278 (July 2001): 330. http://dx.doi.org/10.1016/s0140-6736(01)05505-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lai, Kar Neng, Joseph C. K. Leung, Chun Chung Chow, and Clive S. Cockram. "T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production." Acta Endocrinologica 120, no. 5 (May 1989): 602–9. http://dx.doi.org/10.1530/acta.0.1200602.

Full text

Abstract:

Abstract. The present study was undertaken to examine the cellular control arm of the immune response with regard to T lymphocyte proliferation in euthyroid Graves' ophthalmopathy. Twenty patients with euthyroid Graves' ophthalmopathy (7 on antithyroid drugs and 13 on no treatment) and 18 healthy controls were studied in an infection-free period. Mitogen-stimulated cellular interleukin 2 (IL2) receptor expression, soluble interleukin 2 receptor release, and interleukin 2 production, were studied in peripheral blood mononuclear cells cultured for 24 h. The cellular IL2 receptor expression and soluble IL2 receptor release did not differ between the patients and healthy controls. In contrast, IL2 production in response to pokeweed mitogen stimulation was increased in lymphocytes from patients with Graves' ophthalmopathy. The IL2 release did not correlate with the quantities of cellular and soluble IL2 receptor. The mitogen-stimulated cellular IL2 receptor expression, IL2 receptor release, and IL2 production did not differ between patients with or without carbimazole therapy. Despite a suggested role of autoreactive T cells in mediating the development and propagation of autoimmune thyroid disease, this study fails to demonstrate a defective T lymphocyte activation state in patients with Graves' ophthalmopathy during an euthyroid state.

APA, Harvard, Vancouver, ISO, and other styles

4

Kaito, Ken, Hiroko Otsubo, Yoji Ogasawara, Hiroko Kimura, Etsuko Kurihara, Masaru Koike, Masayoshi Aiso, and Masayuki Kobayashi. "Serum Soluble Interleukin-2 Receptor in Eosinophilia." Acta Haematologica 109, no. 1 (December 23, 2002): 23–28. http://dx.doi.org/10.1159/000067274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Buccheri, Gianfranco, Pietro Marino, Armando Preatoni, Domenico Ferrigno, and Gianni A. Moroni. "Soluble Interleukin 2 Receptor in Lung Cancer." Chest 99, no. 6 (June 1991): 1433–37. http://dx.doi.org/10.1378/chest.99.6.1433.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Valsecchi, R., M. Bontempelli, A. Di Landro, G. Imberti, and T. Cainelli. "Soluble interleukin-2 receptor in lichen planus." British Journal of Dermatology 125, no. 4 (October 1991): 403–4. http://dx.doi.org/10.1111/j.1365-2133.1991.tb14186.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wyman, Michael L., and William D. Engle. "Usefulness of soluble interleukin-2 receptor specificity." Journal of Pediatrics 128, no. 3 (March 1996): 445. http://dx.doi.org/10.1016/s0022-3476(96)70317-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hisamatsu, Ken-ichi, Tetsuya Ganbo, Tsutomu Nakazawa, Shin-ichi Shimomura, Shigetoshi Horiguchi, Mayumi Nakajima, Yoshihiko Murakami, and Hazime Inoue. "Soluble Interleukin-2 Receptor in Nasal Allergy." Practica oto-rhino-laryngologica. Suppl. 1995, Supplement79 (1995): 153–57. http://dx.doi.org/10.5631/jibirinsuppl1986.1995.supplement79_153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Shu, Kuo‐Hsiung, Yuan‐San Lu, Chi‐Hung Cheng, and Jong‐Da Lian. "Soluble Interleukin 2 Receptor in Dialyzed Patients." Artificial Organs 22, no. 2 (February 1998): 142–44. http://dx.doi.org/10.1046/j.1525-1594.1998.05062.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Colver, G. B., J. A. Symons, and G. W. Duff. "Soluble interleukin 2 receptor in atopic eczema." BMJ 298, no. 6685 (May 27, 1989): 1426–28. http://dx.doi.org/10.1136/bmj.298.6685.1426.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Louis, E., J. Belaiche, C. Van Kemseke, N. Schaaf, P. Mahieu, and J. Y. Mary. "Soluble interleukin-2 receptor in Crohn's disease." Digestive Diseases and Sciences 40, no. 8 (August 1995): 1750–56. http://dx.doi.org/10.1007/bf02212697.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Uziel, Yosef, Bernice R. Krafchik, Brian Feldman, Earl D. Silverman, Laurence A. Rubin, and Ronald M. Laxer. "Serum levels of soluble interleukin-2 receptor." Arthritis & Rheumatism 37, no. 6 (June 1994): 898–901. http://dx.doi.org/10.1002/art.1780370618.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Shaarawy, Mohamed, Nabil A. Darwish, and Omar Abdel-Aziz. "Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Gestrational Trophoblastic Diseases." Journal of the Society for Gynecologic Investigation 3, no. 1 (January 1996): 39–46. http://dx.doi.org/10.1177/107155769600300109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

SHAARAWY, M., N. DARWISH, and O. ABDELAZIZ. "Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases." Journal of the Society for Gynecologic Investigation 3, no. 1 (January 1996): 39–46. http://dx.doi.org/10.1016/1071-5576(95)00036-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lai, Kar Neng, Joseph C. K. Leung, and Fernand MacMoune Lai. "Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro." Pathology 23, no. 3 (1991): 224–28. http://dx.doi.org/10.3109/00313029109063570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Murakami, Saburo, Akira Satomi, Kiyoshi Ishida, Hideaki Murai, and Yuima Okamura. "Serum Soluble Interleukin-2 Receptor in Colorectal Cancer." Acta Oncologica 33, no. 1 (January 1994): 19–21. http://dx.doi.org/10.3109/02841869409098369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Pizzolo, Giovanni, Marco Chilosi, and Gianpietro Semenzato. "THE SOLUBLE INTERLEUKIN-2 RECEPTOR IN HAEMATOLOGICAL DISORDERS." British Journal of Haematology 67, no. 4 (December 1987): 377–80. http://dx.doi.org/10.1111/j.1365-2141.1987.tb06156.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Durda, Peter, Jeremy Sabourin, Ethan M. Lange, Mike A. Nalls, Josyf C. Mychaleckyj, Nancy Swords Jenny, Jin Li, et al. "Plasma Levels of Soluble Interleukin-2 Receptor α." Arteriosclerosis, Thrombosis, and Vascular Biology 35, no. 10 (October 2015): 2246–53. http://dx.doi.org/10.1161/atvbaha.115.305289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

IPPOLITI, G., M. VIGANO, and G. PIZZOLO. "SOLUBLE INTERLEUKIN-2 RECEPTOR IN HEART TRANSPLANT RECIPIENTS." Transplantation 52, no. 1 (July 1991): 182. http://dx.doi.org/10.1097/00007890-199107000-00046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Gaughran, F., E. O'Neill, M. Cole, K. Collins, R. J. Daly, and F. Shanahan. "Increased soluble interleukin 2 receptor levels in schizophrenia." Schizophrenia Research 29, no. 3 (February 1998): 263–67. http://dx.doi.org/10.1016/s0920-9964(97)00099-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Shenton, B. "The monitoring of soluble interleukin 2 receptor levels." Immunology Letters 29, no. 1-2 (July 1991): 177. http://dx.doi.org/10.1016/0165-2478(91)90229-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rubin, Laurence A. "The soluble interleukin-2 receptor in rheumatic disease." Arthritis & Rheumatism 33, no. 8 (August 17, 2010): 1145–48. http://dx.doi.org/10.1002/art.1780330814.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Gonda, Kenji, Shoichiro Horita, Yuko Maejima, Seiichi Takenoshita, and Kenju Shimomura. "Soluble interleukin-2 receptor as a predictive and prognostic marker for patients with familial breast cancer." Science Progress 104, no. 3 (July 2021): 003685042110395. http://dx.doi.org/10.1177/00368504211039590.

Full text

Abstract:

The incidence of breast cancer increases annually, and it has become common within families of breast cancer patients. Interleukin-2 activates cytotoxic T lymphocytes, which are important for cancer immunity. To identify markers of increased familial breast cancer risk, soluble interleukin-2 receptor levels and immunologic factors were investigated in familial breast cancer and non-familial breast cancer patients. Of 106 untreated breast cancer patients in this study, 24 had familial breast cancer and 82 had non-familial breast cancer. The patients’ soluble interleukin-2 receptor, interleukin-10, vascular endothelial growth factor, interleukin-17, regulatory T cell, myeloid-derived suppressor cell, white blood cell, and C-reactive protein levels, and their neutrophil-to-lymphocyte ratios were measured, and their prognoses were compared according to the soluble interleukin-2 receptor levels. Additionally, postoperative tissues from the patients with high soluble interleukin-2 receptor levels were stained with programmed cell death ligand 1 and cluster of differentiation 8. The soluble interleukin-2 receptor level in the familial breast cancer patients was significantly higher, and it showed significantly stronger correlations with the neutrophil-to-lymphocyte ratio and the interleukin-10, vascular endothelial growth factor, interleukin-17, regulatory T cell, myeloid-derived suppressor cell, white blood cell, and C-reactive protein levels, than in the non-familial breast cancer patients. The regulatory T cell and myeloid-derived suppressor cell levels were significantly higher in the patients with high soluble interleukin-2 receptor levels, and the overall survival and disease-free-survival rates were significantly worse for the familial breast cancer patients than for the non-familial breast cancer patients. Triple-negative breast cancer tissues from the familial breast cancer patients with high soluble interleukin-2 receptor levels stained well for programmed cell death ligand 1 and cluster of differentiation 8. Soluble interleukin-2 receptor levels can be used to predict the prognosis of familial breast cancer patients. Prospectively identifying patients who are less likely to have non-familial breast cancer is vital for improving their overall survival.

APA, Harvard, Vancouver, ISO, and other styles

24

Nakanishi, Kimio, Yoshiyasu Taniguchi, and Yasuyuki Ohta. "Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease." Acta Endocrinologica 125, no. 3 (September 1991): 253–58. http://dx.doi.org/10.1530/acta.0.1250253.

Full text

Abstract:

Abstract. We measured soluble interleukin 2 receptor, a part of the Tac protein (p55), in peripheral blood to study the immunological condition of the T cell in autoimmune thyroid disease. In 26 patients with untreated Graves' disease and 7 hyperthyroid patients with Hashimoto's thyroiditis, the mean levels of soluble IL-2 receptor were both significantly higher than in normal controls (1497±649 (mean ± sd), 641±137 vs 221±63 103 U/l, p<0.001). There was good correlation between soluble IL-2 receptor levels and blood thyroxine levels (r=0.684, p<0.001) in patients with untreated Graves' disease, but no correlation of soluble IL-2 receptor with TSH-inhibitory immunoglobulins, TS-ab, thyroidal autoantibodies to thyroglobulin and thyroidal microsomal antigen was found. We thought that the level of soluble IL-2 receptor is not dependent only on immunological conditions, but also on thyroid hormone status. When T3 was administered to subjects in remission from Graves' disease and in normal controls, the soluble IL-2 receptor levels significantly increased. Moreover, the mean level of soluble IL-2 receptor in patients with toxic multinodular goitre was also significantly higher than in normal controls (411±148 vs 221±63 103U/l, p<0.05). We conclude that the soluble IL-2 receptor levels are higher in sera of subjects with elevated levels of thyroid hormone.

APA, Harvard, Vancouver, ISO, and other styles

25

Greally, P., M. J. Hussain, J. F. Price, and R. Coleman. "Interleukin-1 alpha and soluble interleukin-2 receptor in atopic dermatitis." Archives of Disease in Childhood 67, no. 11 (November 1, 1992): 1413. http://dx.doi.org/10.1136/adc.67.11.1413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Rapaport, Mark Hyman, and Murray B. Stein. "Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia." Anxiety 1, no. 2 (1994): 50–53. http://dx.doi.org/10.1002/anxi.3070010203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Pforte, A., A. Brunner, P. Gais, G. Burger, G. Breyer, M. Ströbel, K. Häussinger, and H. W. L. Ziegler-Heitbrock. "Concomitant Modulation of Serum-soluble Interleukin-2 Receptor and Alveolar Macrophage Interleukin-2 Receptor in Sarcoidosis." American Review of Respiratory Disease 147, no. 3 (March 1993): 717–22. http://dx.doi.org/10.1164/ajrccm/147.3.717.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Sabat, R., E. Wallace, K. Asadullah, W. Sterry, H. D. Volk, and K. Wolk. "Soluble Receptors of the Interleukin-10 Family of Cytokines: Interleukin-22 Receptor Alpha 2." Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5, no. 3 (August 1, 2006): 215–21. http://dx.doi.org/10.2174/187152306778017692.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Abbate, I., M. Correale, M. D. Musci, M. Guida, C. D. Dragone, M. De Santis, and M. De Lena. "Modification of Soluble Immunological Parameters during Treatment with Interleukin-2." International Journal of Biological Markers 8, no. 4 (October 1993): 227–32. http://dx.doi.org/10.1177/172460089300800405.

Full text

Abstract:

In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9×106 IU/m2 twice daily for 2 days followed by 1.8×106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p<0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.

APA, Harvard, Vancouver, ISO, and other styles

30

Ilias, Ioannis, Georgios Panoutsopoulos, Nikiforos Filippou, Anna Dima, Ioulia Christakopoulou, and Paraskevi Roussou. "Soluble Interleukin 2 Receptors' Levels Versus Thyroid Hormones Levels in Nonthyroidal Disease." Acta Medica (Hradec Kralove, Czech Republic) 42, no. 1 (1999): 13–14. http://dx.doi.org/10.14712/18059694.2019.139.

Full text

Abstract:

Serum soluble interleukin-2 receptor levels, basal thyrotropin, total thyroxine, total triiodothyronine and free triodothyronine were assayed in 29 - otherwise healthy - patients with pulmonary tuberculosis before initiation of anti-tuberculosis treatment and after two weeks of therapy. Twenty seven out of 29 patients presented low-normal total triiodothyronine levels, showing a statistical elevation after anti-tuberculosis therapy. Total triiodothyronine levels before anti-tuberculosis therapy were inversely correlated with levels of serum soluble interleukin-2 receptors. Further investigation on the relationship between soluble interleukin-2 receptorÕs levels and thyroid hormones in non-thyroidal disease can be envisaged.

APA, Harvard, Vancouver, ISO, and other styles

31

Maes, Michael, Herbert Y. Meltzer, Eugène Bosmans, Raf Bergmans, Eric Vandoolaeghe, Rakesch Ranjan, and Roger Desnyder. "Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression." Journal of Affective Disorders 34, no. 4 (August 1995): 301–9. http://dx.doi.org/10.1016/0165-0327(95)00028-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Chen, Luke Y. C., Anna Hayden, and Andre Mattman. "Extreme hyperferritinaemia, soluble interleukin‐2 receptor, and haemophagocytic lymphohistiocytosis." British Journal of Haematology 185, no. 3 (September 11, 2018): 605–6. http://dx.doi.org/10.1111/bjh.15579.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Konda, Ryuichiro, Kiyohide Sakai, Shozo Ota, Atsushi Takeda, Naoki Chida, Hiroshi Sato, and Seiichi Orikasa. "SOLUBLE INTERLEUKIN-2 RECEPTOR IN CHILDREN WITH REFLUX NEPHROPATHY." Journal of Urology 159, no. 2 (February 1998): 535–39. http://dx.doi.org/10.1016/s0022-5347(01)63979-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Chumpitazi, B. F. F., B. Lebeau, C. Legeais, F. Peyron, S. Picot, P. Ambroise-Thomas, and R. Grillot. "Soluble Interleukin-2 Receptor Is Involved during Systemic Mycosis." Journal of Infectious Diseases 168, no. 3 (September 1, 1993): 800–801. http://dx.doi.org/10.1093/infdis/168.3.800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Spear, Michael L., John L. Stefano, Roy Proujansky, and Paul Fawcett. "Reply to: Usefulness of soluble interleukin-2 receptor specificity." Journal of Pediatrics 128, no. 3 (March 1996): 445–46. http://dx.doi.org/10.1016/s0022-3476(96)70318-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lang, Bianca A., Earl D. Silverman, Ronald M. Laxer, Vera Rose, David L. Nelson, and Laurence A. Rubin. "Serum-soluble interleukin-2 receptor levels in Kawasaki disease." Journal of Pediatrics 116, no. 4 (April 1990): 592–96. http://dx.doi.org/10.1016/s0022-3476(05)81610-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Miedel, M. C., J. D. Hulmes, and Y. C. Pan. "Limited proteolysis of recombinant human soluble interleukin-2 receptor." Journal of Biological Chemistry 264, no. 35 (December 1989): 21097–105. http://dx.doi.org/10.1016/s0021-9258(19)30051-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Yorioka, Noriaki, Akira Hirabayashi, Koji Kanahara, Atsuo Takemasa, Hiroaki Oda, Zahid Hossain Joarder, and Michio Yamakido. "Serum Soluble Interleukin-2 Receptor in Patients with Glomerulonephritis." American Journal of Nephrology 10, no. 3 (1990): 181–85. http://dx.doi.org/10.1159/000168078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

OTTAIANO, A., E. LEONARDI, E. SIMEONE, P. ASCIERTO, S. SCALA, R. CALEMMA, J. BRYCE, C. CARACO, R. SATRIANO, and N. GIANFRANCO. "Soluble interleukin-2 receptor in stage I–III melanoma." Cytokine 33, no. 3 (February 7, 2006): 150–55. http://dx.doi.org/10.1016/j.cyto.2006.01.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yorioka, Noriaki, Takahiko Ogawa, Koji Kanahara, Hiroaki Oda, Naoki Hamaguchi, Norihisa Takasugi, Kenichiro Shigemoto, Michiko Arita, and Satoru Harada. "Serum soluble interleukin 2 receptor in maintenance hemodialysis patients." Journal of Japanese Society for Dialysis Therapy 23, no. 3 (1990): 319–22. http://dx.doi.org/10.4009/jsdt1985.23.319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Gilad, R., Y. Lampl, Y. Eshel, V. Barak, and I. Sarova-Pinhas. "Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus." Rheumatology 36, no. 2 (February 1, 1997): 190–93. http://dx.doi.org/10.1093/rheumatology/36.2.190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Nässberger, L., and L. Träskman-Bendz. "Increased soluble interleukin-2 receptor concentrations in suicide attempters." Acta Psychiatrica Scandinavica 88, no. 1 (July 1993): 48–52. http://dx.doi.org/10.1111/j.1600-0447.1993.tb03412.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chen, H. S., M. S. Wu, T. S. Yen, and W. Y. Chen. "Soluble interleukin-2 receptor in patients with glomerular diseases." Postgraduate Medical Journal 71, no. 840 (October 1, 1995): 617–22. http://dx.doi.org/10.1136/pgmj.71.840.617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Petereit, Hela-Felicitas, Dirk Reske, Hayrettin Tumani, Sven Jarius, F. Markus Leweke, Dirk Woitalla, Hans-Walter Pfister, and Andrea Rubbert. "Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis." Journal of Neurology 257, no. 11 (June 17, 2010): 1855–63. http://dx.doi.org/10.1007/s00415-010-5623-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Penedo-Pita, Manuel, and Javier Peteiro-Cartelle. "Increased Serum Levels of Interleukin-2 and Soluble Interleukin-2 Receptor in Celiac Disease." Journal of Pediatric Gastroenterology and Nutrition 12, no. 1 (January 1991): 56–60. http://dx.doi.org/10.1097/00005176-199101000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kasumagic-Halilovic, Emina, Nermina Ovcina-Kurtovic, Samra Soskic, Hana Helppikangas, and Ognjen Ridic. "Serum Levels of Interleukin-2 and Interleukin-2 Soluble Receptor in Patients with Vitiligo." British Journal of Medicine and Medical Research 13, no. 10 (January 10, 2016): 1–7. http://dx.doi.org/10.9734/bjmmr/2016/23959.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Shimomura, Tokio, Shigeru Araga, Eisaku Esumi, Etsuko Awaki, and Kazuro Takahashi. "Serum Interleukin-2 and Soluble Interleukin-2 Receptor Levels in Patients with Chronic Headache." Cephalalgia 11, no. 11_suppl (June 1991): 285–86. http://dx.doi.org/10.1177/0333102491011s11153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Shimomura, Toklo, Shigeru Araga, Etsuko Awaki, Hisanori Kowa, and Kazuro Takahashi. "Serum interleukin-2 and soluble interleukin-2 receptor levels in patients with chronic headache." Journal of the Autonomic Nervous System 41, no. 3 (December 1992): 237. http://dx.doi.org/10.1016/0165-1838(92)90080-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Kondo, Nobuo, Shigeru Kondo, Akira Shimizu, Tasuku Honjo, and Junji Hamuro. "A soluble ’anchorminus‘ interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses." Immunology Letters 19, no. 4 (December 1988): 299–307. http://dx.doi.org/10.1016/0165-2478(88)90159-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Zielinski, C. C., B. Pesau, and Ch Müller. "Soluble interleukin-2 receptor and soluble CD8 antigen in active rheumatoid arthritis." Clinical Immunology and Immunopathology 57, no. 1 (October 1990): 74–82. http://dx.doi.org/10.1016/0090-1229(90)90023-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Soluble interleukin-2 receptor'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles